Nerlynx (neratinib) vs Kadcyla (trastuzumab emtansine)
Nerlynx (neratinib) vs Kadcyla (trastuzumab emtansine)
Nerlynx (neratinib) is an oral tyrosine kinase inhibitor specifically designed to block certain enzymes that promote cell growth in HER2-positive breast cancer, and it is typically used as an extended adjuvant treatment following initial therapy. Kadcyla (trastuzumab emtansine) is an intravenous drug that combines the HER2-targeting properties of trastuzumab with the chemotherapy agent DM1; it is used to treat HER2-positive breast cancer that has either recurred or is unresectable and has previously been treated with trastuzumab and a taxane. The choice between Nerlynx and Kadcyla will depend on the specific characteristics of the cancer, previous treatments, and individual patient factors such as tolerance to therapy and presence of metastases, which should be thoroughly discussed with an oncologist.
Difference between Nerlynx and Kadcyla
Metric | Nerlynx (neratinib) | Kadcyla (trastuzumab emtansine) |
---|---|---|
Generic name | Neratinib | Trastuzumab emtansine |
Indications | Extended adjuvant treatment of HER2-positive breast cancer | Treatment of HER2-positive metastatic breast cancer |
Mechanism of action | Tyrosine kinase inhibitor | Antibody-drug conjugate targeting HER2 receptors |
Brand names | Nerlynx | Kadcyla |
Administrative route | Oral | Intravenous |
Side effects | Diarrhea, nausea, abdominal pain, fatigue, rash | Fatigue, nausea, musculoskeletal pain, hemorrhage, thrombocytopenia |
Contraindications | Severe liver impairment, severe hypersensitivity to neratinib | Hypersensitivity to trastuzumab emtansine or any of its components |
Drug class | Tyrosine kinase inhibitor | Antibody-drug conjugate |
Manufacturer | Puma Biotechnology | Genentech (Roche) |
Efficacy
Nerlynx (Neratinib) Efficacy in Breast Cancer
Nerlynx (neratinib) is an oral medication that is used as an adjuvant treatment for breast cancer. Specifically, it is indicated for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Clinical trials have demonstrated that neratinib effectively reduces the risk of breast cancer recurrence. In the ExteNET study, a phase III randomized trial, patients who received neratinib after standard adjuvant therapy with trastuzumab had a statistically significant improvement in invasive disease-free survival compared to those who received placebo.
Kadcyla (Trastuzumab Emtansine) Efficacy in Breast Cancer
Kadcyla (trastuzumab emtansine) is a targeted therapy used to treat HER2-positive metastatic breast cancer. It combines the HER2-targeting properties of trastuzumab with the chemotherapy agent emtansine. Kadcyla is specifically indicated for patients who have previously received trastuzumab and a taxane, separately or in combination. Patients who receive Kadcyla have been shown to have a significant improvement in both progression-free survival and overall survival compared to those receiving standard therapies. The EMILIA study, a pivotal phase III clinical trial, demonstrated these benefits, establishing Kadcyla as a valuable treatment option for patients with advanced HER2-positive breast cancer.
Comparative Efficacy and Considerations
While both Nerlynx and Kadcyla are used in the treatment of HER2-positive breast cancer, their indications and points of intervention in the treatment pathway differ. Nerlynx is primarily used in the early-stage setting as an extended adjuvant therapy, whereas Kadcyla is used in metastatic cases or after recurrence. The choice between these medications depends on several factors, including the stage of the disease, prior treatments, and the specific characteristics of the cancer. Both drugs have been shown to improve outcomes for patients with HER2-positive breast cancer, but their efficacy must be considered within the context of the individual patient's treatment plan.
Conclusion
In conclusion, Nerlynx and Kadcyla have both demonstrated efficacy in improving outcomes for patients with HER2-positive breast cancer, albeit at different stages of the disease. The use of these targeted therapies represents a significant advancement in the treatment of breast cancer, offering hope for improved survival and quality of life for patients. As with any medication, the efficacy of Nerlynx and Kadcyla should be evaluated by healthcare professionals in the context of each patient's unique clinical situation.
Regulatory Agency Approvals
Nerlynx
Kadcyla
Access Nerlynx or Kadcyla today
If Nerlynx or Kadcyla are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us